Sichenzia Ross Ference LLP Represents Boustead Securities, LLC as Underwriter to MAINZ BIOMED B.V. in $11.5 Million U.S. Initial Public Offering
Press Release – New York, NY – November 11, 2021 – Sichenzia Ross Ference LLP congratulates MAINZ BIOMED B.V. (the “Company”) (NASDAQ: MYNZ ), a molecular genetics diagnostic company specializing in the early detection of cancer, on the final closing of its initial public offering on November 9, 2021. The Company raised $11.5 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 2,300,000 common shares at a public offering price of $5.00 per share. The ordinary shares commenced trading on the Nasdaq Capital Market on November 5, 2021 under the ticker symbol “MYNZ”.
Boustead Securities, LLC acted as the sole underwriter for the offering and the Firm acted as legal counsel to the underwriter. The Sichenzia Ross Ference LLP team was led by Senior Partner, Benjamin Tan.
- Sichenzia Ross Ference LLP Represents Good Gaming, Inc. in $3.1 Million Private Placement Offering - November 18, 2021
- The Growing Risk of Website Accessibility Litigation and How to Protect Your Business Against It - November 18, 2021
- Sichenzia Ross Ference LLP Represents Boustead Securities, LLC as Underwriter to MAINZ BIOMED B.V. in $11.5 Million U.S. Initial Public Offering - November 10, 2021